<code id='1F75C47C15'></code><style id='1F75C47C15'></style>
    • <acronym id='1F75C47C15'></acronym>
      <center id='1F75C47C15'><center id='1F75C47C15'><tfoot id='1F75C47C15'></tfoot></center><abbr id='1F75C47C15'><dir id='1F75C47C15'><tfoot id='1F75C47C15'></tfoot><noframes id='1F75C47C15'>

    • <optgroup id='1F75C47C15'><strike id='1F75C47C15'><sup id='1F75C47C15'></sup></strike><code id='1F75C47C15'></code></optgroup>
        1. <b id='1F75C47C15'><label id='1F75C47C15'><select id='1F75C47C15'><dt id='1F75C47C15'><span id='1F75C47C15'></span></dt></select></label></b><u id='1F75C47C15'></u>
          <i id='1F75C47C15'><strike id='1F75C47C15'><tt id='1F75C47C15'><pre id='1F75C47C15'></pre></tt></strike></i>

          explore

          explore

          author:comprehensive    Page View:16
          HHS 2020
          PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

          WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

          The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

          advertisement

          PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Doudna institute plans to 'cure hundreds of diseases' with CRISPR
          Doudna institute plans to 'cure hundreds of diseases' with CRISPR

          ChristineKao/STATResearchersattendinggenetherapymeetingsoverthepastcoupleyearswereliabletobumpintoas

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Doudna institute plans to 'cure hundreds of diseases' with CRISPR

          ChristineKao/STATResearchersattendinggenetherapymeetingsoverthepastcoupleyearswereliabletobumpintoas